Core Insights - Organovo Holdings, Inc. has successfully closed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company on March 25, 2025 [1][2] Group 1: Transaction Details - Organovo will receive an upfront payment and future milestone payments as FXR314 achieves key regulatory and commercial milestones [2] - Eli Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development and will handle all future clinical development [2] Group 2: Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues [3] - The company utilizes proprietary technology to create 3D human tissues that replicate essential aspects of native human tissue composition, architecture, function, and disease [3]

As filed with the Securities and Exchange Commission on April 30, 2024 Registration No. 333-278668 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Organovo Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 27-1488943 (Primary Standard Classification Code Number) 11555 Sorrento Valley Road, Suite 100 (I.R.S ...

As filed with the Securities and Exchange Commission on April 12, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Organovo Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Classification Code Number) 11555 Sorrento Valley Road, Suite 100 San Diego, CA 92121 (858) 224-1000 Delaware 2836 27-1488943 (I.R.S. Employer I ...